IMPROVED SURVIVAL BUT NOT LEFT-VENTRICULAR FUNCTION WITH EARLY AND PREHOSPITAL TREATMENT WITH TISSUE PLASMINOGEN-ACTIVATOR IN ACUTE MYOCARDIAL-INFARCTION

被引:59
作者
BARBASH, GI
ROTH, A
HOD, H
MILLER, HI
MODAN, M
RATH, S
ZAHAV, YH
SHACHAR, A
BASAN, S
BATTLER, A
RABINOWITZ, B
KAPLINSKY, E
SELIGSOHN, U
LANIADO, S
机构
[1] CHAIM SHEBA MED CTR, INST CARDIOL, IL-52621 TEL HASHOMER, ISRAEL
[2] TEL AVIV MED CTR & SCH MED, INST CARDIOL, TEL AVIV, ISRAEL
[3] TEL AVIV UNIV, SACKLER SCH MED, DEPT EPIDEMIOL & BIOSTAT, TEL AVIV, ISRAEL
[4] TEL AVIV MED CTR & SCH MED, INST HEMATOL, TEL AVIV, ISRAEL
关键词
D O I
10.1016/0002-9149(90)90832-L
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
One hundred ninety patients with acute myocardial infarction (AMI) were treated with recombinant tissue-type plasminogen activator (rt-PA) 2.0 ± 0.8 hours after the onset of symptoms. Eighty-seven patients were enrolled via mobile intensive care units and 103 through the emergency ward. Patients who were enrolled via the mobile intensive care units were randomized to immediate, prehospital treatment initiation, or to delayed, in-hospital treatment initiation. All 190 patients except 2 underwent delayed coronary angiography and, when indicated, angioplasty at 72 hours after enrollment. Patients treated within 2 hours and those treated 2 to 4 hours after symptom onset had similar preservation of left ventricular function, and similar prevalence of congestive heart failure at discharge. Patients treated within 2 hours of symptom onset had significantly lower short- (0.0 vs 6.3%, p = 0.01) and long-term (1.0 vs 9.5%, p = 0.03) mortality. Prehospital initiation of rt-PA appeared to be safe and feasible and resulted in a 40-minute decrease in the time from symptom onset to treatment initiation. © 1990.
引用
收藏
页码:261 / 266
页数:6
相关论文
共 12 条
  • [1] [Anonymous], 1987, LANCET, V2, P871
  • [2] [Anonymous], 1986, LANCET, V1, P397
  • [3] REVERSIBLE ISCHEMIC LEFT-VENTRICULAR DYSFUNCTION - EVIDENCE FOR THE HIBERNATING MYOCARDIUM
    BRAUNWALD, E
    RUTHERFORD, JD
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (06) : 1467 - 1470
  • [4] CHAMBERLAIN DA, 1988, LANCET, V1, P545
  • [5] PREVENTION OF MYOCARDIAL DAMAGE IN ACUTE MYOCARDIAL ISCHEMIA BY EARLY TREATMENT WITH INTRAVENOUS STREPTOKINASE
    KOREN, G
    WEISS, AT
    HASIN, Y
    APPELBAUM, D
    WELBER, S
    ROZENMAN, Y
    LOTAN, C
    MOSSERI, M
    SAPOZNIKOV, D
    LURIA, MH
    GOTSMAN, MS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (22) : 1384 - 1389
  • [6] TIME FROM ONSET OF SYMPTOMS TO THROMBOLYTIC THERAPY - A MAJOR DETERMINANT OF MYOCARDIAL SALVAGE IN PATIENTS WITH ACUTE TRANSMURAL INFARCTION
    MATHEY, DG
    SHEEHAN, FH
    SCHOFER, J
    DODGE, HT
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1985, 6 (03) : 518 - 525
  • [7] THE GERMAN MULTICENTER TRIAL OF ANISOYLATED PLASMINOGEN STREPTOKINASE ACTIVATOR COMPLEX VERSUS HEPARIN FOR ACUTE MYOCARDIAL-INFARCTION
    MEINERTZ, T
    KASPER, W
    SCHUMACHER, M
    JUST, H
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (07) : 347 - 351
  • [8] EARLY INTERVENTION IN ACUTE MYOCARDIAL-INFARCTION - SIGNIFICANCE FOR MYOCARDIAL SALVAGE OF IMMEDIATE INTRAVENOUS STREPTOKINASE THERAPY FOLLOWED BY CORONARY ANGIOPLASTY
    MILLER, HI
    ALMAGOR, Y
    KEREN, G
    CHERNILAS, J
    ROTH, A
    ESCHAR, Y
    SHAPIRA, I
    SHARGORODSKY, B
    BERENFELD, D
    LANIADO, S
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 9 (03) : 608 - 614
  • [9] PASSAMANI E, 1985, NEW ENGL J MED, V312, P932
  • [10] VENTRICULAR-FUNCTION AND INFARCT SIZE - THE WESTERN WASHINGTON INTRAVENOUS STREPTOKINASE IN MYOCARDIAL-INFARCTION TRIAL
    RITCHIE, JL
    CERQUEIRA, M
    MAYNARD, C
    DAVIS, K
    KENNEDY, JW
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 11 (04) : 689 - 697